Published in
American Society of Hematology, Blood, 6(127), p. 749-760, 2016
DOI: 10.1182/blood-2015-04-640128
Links
- ORCID
- ORCID
- ORCID
- American Society of Hematology | PDF
- ORCID
- ORCID
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
Tools
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion
Journal article published in 2015 by
Virginie Chesnais,
Aline Renneville 
,
Andrea Toma,
Jérôme Lambert,
Marie Passet,
Florent Dumont,
Sylvie Chevret ,
Julie Lejeune,
Anna Raimbault,
Aspasia Stamatoullas,
Christian Rose,
Odile Beyne-Rauzy,
Jacques Delaunay,
Eric Solary ,
Pierre Fenaux
and other authors.
,
Andrea Toma,
Jérôme Lambert,
Marie Passet,
Florent Dumont,
Sylvie Chevret ,
Julie Lejeune,
Anna Raimbault,
Aspasia Stamatoullas,
Christian Rose,
Odile Beyne-Rauzy,
Jacques Delaunay,
Eric Solary ,
Pierre Fenaux
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Lenalidomide treatment has variable transient effects on the clonal architecture of myelodysplastic syndromes without 5q deletion. Lenalidomide is unlikely to eradicate myelodysplastic clones characterized by combinations of SF3B1, TET2, DNMT3A, and ASXL1 mutations.